|
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This phase 2 study compared erlotinib with and without emibetuzumab in first-line treatment of EGFR-mutant metastatic NSCLC.
|
31622732 |
2020 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
<b>Introduction</b>: Cancer immunotherapy has revolutionized the treatment of patients with advanced or metastatic non-small cell lung cancer (NSCLC).However, specific patient groups (e.g. patients with activating <i>epidermal growth factor receptor</i> [<i>EGFR]</i> mutations) do not appear to derive benefit from immune checkpoint inhibitor (ICI) monotherapy.
|
31829747 |
2020 |
|
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
This concept was applied to the use of noninvasive plasma epidermal growth factor receptor (EGFR) mutation testing in patients with advanced or metastatic non-small cell lung cancer (NSCLC) to guide treatment with EGFR tyrosine kinase inhibitors (TKIs).
|
31125533 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To determine factors associated with survival in de novo stage IV, non-small cell lung cancer (NSCLC) patients possessing epidermal growth factor receptor mutations (EGFRmut<sup>+</sup> ) receiving tyrosine kinase inhibitors (TKI) in the first-line setting.
|
31486229 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We performed a retrospective review of 18 patients with histologically proven (+) EGFR (+) mutation metastatic NSCLC (mNSCLC) treated with 75 mg/d erlotinib as starting dose.
|
31567201 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We collected data from EGFR TKI-naive patients with metastatic NSCLC, harboring EGFR exon 18 mutations and EGFR combined mutations treated with first- or second-generation EGFR TKIs.
|
30563752 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We conducted an intervention study involving 126 individuals with confirmed activating epidermal growth factor receptor mutation-positive stage IV NSCLC who received icotinib hydrochloride as first-line therapy between January 2014 and January 2016; their caregivers were also included in the study.
|
29731164 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The clinical data of patients with brain metastatic NSCLC who had EGFR-sensitive mutation and followed between January 2014 and January 2016 was retrospectively analyzed.
|
31128009 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Despite their remarkable efficacy in metastatic non-small cell lung cancer (NSCLC), EGFR- and ALK-targeted therapies have not been shown to confer any survival benefit in stage III disease, even in subsets of patients with driver mutations.
|
30711973 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this study was to investigate the prevalence, characteristics, and clinical outcomes of metastatic NSCLC harboring uncommon EGFR mutation at Thailand's largest national tertiary hospital.
|
31315599 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
A 66-year-old man was diagnosed with relapsed stage IV non-small cell lung cancer with an EGFR mutation in exon 21 (L858R) 2 years after stereotactic body radiotherapy.
|
31486987 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
A high pretreatment PLR is independently associated with poor survival in stage IV NSCLC with MPE and in a subgroup of epidermal growth factor receptor and anaplastic lymphoma kinase wild-type NSCLC.
|
30886226 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The RELAY regimen is a viable new treatment option for the initial treatment of EGFR-mutated metastatic NSCLC.
|
31591063 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
The second-generation EGFR-TKI dacomitinib has also recently been approved for the first-line treatment of EGFRm positive metastatic NSCLC.
|
31568888 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Eligible patients were adults (≥18 years) with previously untreated locally advanced or metastatic non-small-cell lung cancer without a sensitising EGFR mutation or ALK translocation and with an Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, life expectancy 3 months or longer, and a PD-L1 TPS of 1% or greater.
|
30955977 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To assess the utility of the <b>cobas</b> EGFR Mutation Test, with tissue and plasma, for first-line osimertinib therapy for patients with <i>EGFR</i>-mutated (<i>EGFR</i>m; Ex19del and/or L858R) advanced or metastatic non-small cell lung cancer (NSCLC) from the FLAURA study (NCT02296125).
|
31439584 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We explored EGFR-TKI treatment attribute preferences in EGFR mutation-positive metastatic non-small-cell lung cancer.
|
31621403 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The drug is approved for the first-line treatment of patients with metastatic non-small cell lung cancer with EGFR mutations.
|
30729434 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) represent the standard of care for patients with metastatic non-small-cell lung cancer (NSCLC) harboring sensitizing EGFR mutations.
|
30570396 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
RCTs of second/third line treatments in participants with advanced/metastatic NSCLC and negative/low expression of Anaplastic Lymphoma Kinase (ALK) and of Epidermal Growth Factor Receptor (EGFR) were included.
|
31023244 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Phase I Trial of Targeted EGFR or ALK Therapy with Ipilimumab in Metastatic NSCLC with Long-Term Follow-Up.
|
31346927 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
This study investigated the efficacy and safety of first-line EGFR-TKI combined with thoracic radiotherapy in treating stage IV non-small cell lung cancer (NSCLC) harboring EGFR active mutations.
|
31040256 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
A Systematic Review of Economic Evaluations Assessing the Cost-Effectiveness of Licensed Drugs Used for Previously Treated Epidermal Growth Factor Receptor (EGFR) and Anaplastic Lymphoma Kinase (ALK) Negative Advanced/Metastatic Non-Small Cell Lung Cancer.
|
31583605 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
Biomarker
|
disease |
BEFREE |
Local Consolidation Therapy (LCT) After First Line Tyrosine Kinase Inhibitor (TKI) for Patients With EGFR Mutant Metastatic Non-small-cell Lung Cancer (NSCLC).
|
30343004 |
2019 |
|
Metastatic non-small cell lung cancer
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The European Commission also approved dacomitinib on April 3, 2019, as monotherapy for the first-line treatment of adult patients with locally advanced or metastatic NSCLC with EGFR activating mutations.
|
31050691 |
2019 |